A prospective study of Measurable Residual Disease (MRD) and Sustainability of the Response in Patients with Systemic AL Amyloidosis Treated with Daratumumab
Latest Information Update: 19 Jan 2024
At a glance
- Drugs Daratumumab (Primary)
- Indications Amyloid light-chain amyloidosis
- Focus Therapeutic Use
Most Recent Events
- 19 Jan 2024 New trial record
- 12 Dec 2023 Results presented at the 65th American Society of Hematology Annual Meeting and Exposition